Title:Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Volume: 17
Issue: 16
Author(s): Nagendra Sastry Yarla, Anupam Bishayee, Lakshmipathi Vadlakonda, Ramakrishna Chintala, Govinda Rao Duddukuri, Pallu Reddanna and Kaladhar S.V.G.K. Dowluru
Affiliation:
关键词:
磷脂酶A2、炎症、癌症、PLA2同种型特定抑制剂。
摘要: Phospholipase A2s (PLA2s) are group of enzymes, which cleave phospholipids
specifically at sn-2 position to liberate free fatty acid, mostly arachidonic acid
(AA) and lysophospholipids (LPLs). Inhibition of PLA2 prevents the liberation of AA
and LPLs. Hence, researchers have been considering PLA2s could be a better therapeutic
target than the downstream enzymes cyclooxygense and lipoxygenase. Several
isoforms of PLA2s exist; they are mainly divided into secretory PLA2s (sPLA2), cytosolic
PLA2s (cPLA2), and calcium independent PLA2s (iPLA2), platelet activating factor-
acyl hydrolase (PAF-AH), lysosomal PLA2 (LPLA2), adipose-specific PLA2 (Ad-
PLA). Each isoform of PLA2s is different in its chemical structure and physiological
functions. sPLA2s (Groups IIA, V and X) are well characterized as proinflammatory
mediating enzymes but their role in cancer is controversial. Groups IVA, IVB and IVC cPLA2s are present
in humans but only Group IVA cPLA2 plays key role in pathophysiology of various cancers and
inflammation. The role of iPLA2 in inflammation and cancer is limited. Lipoprotein associated PLA2
(Group VIIA PLA2), a PAF-AH isoform, has key role in atherosclerosis. Several isoform specific PLA2
inhibitors have been developed and some of the PLA2s inhibitors are currently under clinical trials for
various inflammatory and oncologic diseases. This review focuses on the recent experimental evidences
to support the notion that PLA2s are causally implicated in the pathobiology of cancer and inflammatory
related disorders and discuss the potential utility of isoform specific PLA2 inhibitors as preventive
and/or therapeutic agents.
